Neumora Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 124
- Market Cap
- $1.8B
- Website
- http://www.neumoratx.com
- Introduction
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
- Conditions
- Healthy ElderlyAlzheimer's Disease
- Interventions
- Drug: PlaceboDrug: NMRA-323511
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neumora Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06546995
- Locations
- 🇺🇸
Neumora Investigator Site, Mesquite, Texas, United States
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
- Conditions
- Major Depressive Episode Associated With Bipolar II Disorder
- Interventions
- Drug: PlaceboDrug: NMRA-335140 80 mg
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neumora Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06429722
- Locations
- 🇺🇸
Neumora Investigator Site, Brooklyn, New York, United States
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: NMRA-335140Drug: Placebo
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neumora Therapeutics, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT06058013
- Locations
- 🇺🇸
Neumora Investigator Site -2, Tampa, Florida, United States
🇺🇸Neumora Investigator Site-1, Tampa, Florida, United States
🇨🇱Neumora Investigator Site, Antofagasta, Chile
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: NMRA-335140Drug: Placebo
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neumora Therapeutics, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT06058039
- Locations
- 🇸🇪
Neumora Investigator Site, Stockholm, Stockholms Län, Sweden
🇺🇸Neumora Investigator site, Miami, Florida, United States
Study to Assess the Safety and Effectiveness of NMRA-335140-501
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: NMRA-335140
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Neumora Therapeutics, Inc.
- Target Recruit Count
- 650
- Registration Number
- NCT06029439
- Locations
- 🇺🇸
Neumora Investigator site, Austin, Texas, United States
🇸🇪Neumora Investigator Site, Stockholm, Stolkholm Ian, Sweden
🇺🇸Neumora Investigator Site-1, Atlanta, Georgia, United States
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: NMRA-335140Drug: Placebo
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Neumora Therapeutics, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT06029426
- Locations
- 🇺🇸
Neumora Investigator Site, Everett, Washington, United States
🇺🇸Neumora Investigator Site-1, Little Rock, Arkansas, United States
🇺🇸Neumora Investigator Site #1, Sherman Oaks, California, United States